Gan & Lee Pharmaceuticals Co Ltd (603087) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gan & Lee Pharmaceuticals Co Ltd (603087) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥257.27 Million ≈ $37.65 Million USD) by net assets (CN¥11.28 Billion ≈ $1.65 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Gan & Lee Pharmaceuticals Co Ltd (603087) market capitalisation for the company's overall valuation and market capitalisation.
Gan & Lee Pharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Gan & Lee Pharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Gan & Lee Pharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gan & Lee Pharmaceuticals Co Ltd ranked by their cash flow conversion efficiency. Explore 603087 operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Avanza Bank Holding AB (publ)
ST:AZA
|
1.029x |
|
KakaoBank Corp
KO:323410
|
0.190x |
|
Far East Smarter Energy Co Ltd
SHG:600869
|
0.019x |
|
China Natl Chem Engineering Co
SHG:601117
|
0.091x |
|
Macerich Company
NYSE:MAC
|
0.050x |
|
OceanaGold Corporation
TO:OGC
|
0.119x |
|
Life Time Group Holdings Inc
NYSE:LTH
|
0.084x |
|
General Insurance Corporation of India
NSE:GICRE
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Gan & Lee Pharmaceuticals Co Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Gan & Lee Pharmaceuticals Co Ltd from 2013 to 2025. View current stock price of Gan & Lee Pharmaceuticals Co Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥11.63 Billion ≈ $1.70 Billion |
CN¥784.28 Million ≈ $114.76 Million |
0.067x | +38.76% |
| 2024-12-31 | CN¥11.05 Billion ≈ $1.62 Billion |
CN¥537.31 Million ≈ $78.63 Million |
0.049x | +22.09% |
| 2023-12-31 | CN¥10.74 Billion ≈ $1.57 Billion |
CN¥427.69 Million ≈ $62.58 Million |
0.040x | +28.63% |
| 2022-12-31 | CN¥9.59 Billion ≈ $1.40 Billion |
CN¥296.68 Million ≈ $43.41 Million |
0.031x | -70.81% |
| 2021-12-31 | CN¥10.17 Billion ≈ $1.49 Billion |
CN¥1.08 Billion ≈ $157.77 Million |
0.106x | -23.64% |
| 2020-12-31 | CN¥8.94 Billion ≈ $1.31 Billion |
CN¥1.24 Billion ≈ $181.65 Million |
0.139x | -34.16% |
| 2019-12-31 | CN¥5.47 Billion ≈ $800.55 Million |
CN¥1.15 Billion ≈ $168.86 Million |
0.211x | +115.48% |
| 2018-12-31 | CN¥4.27 Billion ≈ $624.94 Million |
CN¥418.04 Million ≈ $61.17 Million |
0.098x | -65.62% |
| 2017-12-31 | CN¥3.34 Billion ≈ $488.07 Million |
CN¥949.60 Million ≈ $138.96 Million |
0.285x | -16.55% |
| 2016-12-31 | CN¥2.26 Billion ≈ $330.10 Million |
CN¥769.63 Million ≈ $112.62 Million |
0.341x | +13.29% |
| 2015-12-31 | CN¥1.49 Billion ≈ $217.41 Million |
CN¥447.42 Million ≈ $65.47 Million |
0.301x | +2.44% |
| 2014-12-31 | CN¥1.04 Billion ≈ $151.93 Million |
CN¥305.22 Million ≈ $44.66 Million |
0.294x | +5.28% |
| 2013-12-31 | CN¥733.22 Million ≈ $107.29 Million |
CN¥204.73 Million ≈ $29.96 Million |
0.279x | -- |
About Gan & Lee Pharmaceuticals Co Ltd
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 inject… Read more